Factor replacement therapy in haemophilia--are there models for developing countries?

Area of Science:

• Hematology
• Orthopedics
• Global Health

Background:

• Severe hemophilia treatment requires high-purity factor concentrates (1500-9000 IU kg-1 year-1) for prophylactic or on-demand administration.
• Prohibitive costs of intensive factor replacement therapy make it impractical in developing countries, where lower doses (25-500 IU kg-1 year-1) are used.

Purpose of the Study:

• To evaluate the long-term musculoskeletal function outcomes in hemophilia patients receiving limited factor replacement therapy.
• To explore feasible models for providing adequate factor replacement therapy in resource-limited settings.

Main Methods:

• Review of existing data on factor replacement therapy protocols and outcomes in developing countries.
• Analysis of the shift in therapeutic goals from joint preservation to functional preservation with lower factor doses.
• Exploration of economic factors influencing product selection (concentrates vs. blood-bank products).

Main Results:

• Joint damage is often inevitable with lower-dose factor replacement therapy.
• A significant portion of patients in developing countries lack access to adequate replacement therapy.
• Economic constraints necessitate the use of varied and sometimes less effective blood products.

Conclusions:

• The primary aim of hemophilia therapy in developing countries shifts to preventing disability and maintaining joint function.
• There is a critical need for studies documenting long-term musculoskeletal outcomes with lower-dose factor replacement.
• Providing virus-inactivated purified factor concentrates for all individuals with hemophilia should be the goal, achievable through local production or importation.